First in man, randomized, double-blind, placebo-controlled, phase I trial assessing INF904 in complement-mediated, chronic autoimmune and inflammatory diseases

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jan 2024 According to InflaRx media release, InflaRx will host a conference call to provide more details about the announced topline results of the MAD part of this study.
04 Jan 2024 Topline results (n=24 from the multiple ascending dose part) presented in the InflaRx Media Release.
11 Sep 2023 According to InflaRx media release, the company will host a conference call to provide more details about the announced topline results of the SAD part.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com